Every material Form 8-K Edwards Lifesciences filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Edwards Lifesciences reported third-quarter 2024 net sales of $1.35 billion, up 9% from a year earlier, with adjusted EPS of $0.67 versus $0.55. It reiterated its 2024 full-year sales growth guidance of 8% to 10% and gave fourth-quarter sales and EPS ranges. GAAP diluted EPS of $5.13 was driven mainly by a one-time gain from discontinued operations tied to the Critical Care sale.
Q3 net sales $1,354.4 million, up 8.9% from $1,243.4 million; TMTT sales up 73%, TAVR up 6%
Edwards reported second-quarter sales of $1,385.9 million, up 7%, and GAAP diluted EPS of $0.61 versus $0.50 a year earlier. It cut full-year TAVR sales growth guidance to 5 to 7% from 8 to 10%, raised TMTT guidance to the higher end of $320 to $340 million, and agreed to buy JenaValve and exercise its option to buy Endotronix for about $1.2 billion in cash plus up to $445 million in milestone payments.
Q2 net sales of $1,385.9 million, up 7% from $1,295.5 million; TMTT sales rose 75% to $83 million
Full-year 2024 TAVR sales growth guidance lowered to 5 to 7% from 8 to 10%; total Edwards sales growth guidance kept at 8 to 10%
Acquisitions of JenaValve and Endotronix carry about $1.2 billion upfront cash plus up to $445 million on milestones, subject to closing conditions
Critical Care sale for $4.2 billion remains on track to close in late Q3 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Edwards Lifesciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →